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Whatever has happened, has happened well 
Whatever is happening, is happening well 
Whatever is due for the future, will happen well 
What did you lose? Why do you worry? 
What did you bring with you, that you think you have lost? 
What did you create, that you think you have destroyed? 
Whatever you have, you received here 
Whatever you gave, you gave it here 
Whatever is yours today will be someone else's tomorrow 
Another day it will be somebody else's 
This is the World’s ordinance and essence of My creation 
-The Bhagavad Gita 
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ABSTRACT 
RNA polymerase I (Pol I)-mediated transcription of ribosomal DNA (rDNA) is considered to 
be the rate-limiting step in ribosome biogenesis and is a well-known hallmark of cell growth 
and proliferation. The process of synthesizing new ribosomes is executed by the coordination 
of multiple complex processes in the nucleolus. The initial step of transcribing 47S ribosomal 
RNA (rRNA) transcript by the Pol I complex is followed by its processing into 28S, 18S and 
5.8S rRNAs. These transcripts, together with 5S rRNA transcribed by Pol III and auxiliary 
proteins transcribed by Pol II, proceed to form a mature ribosome after being exported into the 
cytoplasm. Regulation of ribosome biogenesis occurs in a cell cycle dependent manner, and 
actively transcribing nucleolar organizing regions (NORS) indicating active rDNA 
transcription have been associated with tumor proliferation and poor prognosis in cancer 
patients. Numerous oncogenic and tumor suppressive pathways modulate tumor growth 
through rDNA transcription. We have previously shown that the tumor suppressive effects of 
Wnt5a is mediated though suppression of rDNA transcription by recruitment of Dishevelled 1 
(DVL1) to the nucleolus and the rDNA gene cassette. In this thesis, we show that de novo 
ribosome biogenesis is essential for the epithelial-to-mesenchymal transition (EMT), which is 
indispensable for embryonic development and for the acquisition of migratory phenotype 
during cancer progression. The induced de novo rRNA synthesis occurring in the absence of 
cell proliferation is mediated by increased recruitment of Pol I complex components and EMT 
transcription factor Snail1 to the rDNA gene cassette. This is accompanied by the opening of 
the otherwise silenced rDNA operons by the release of TTF-I interacting protein 5 (TIP5), a 
major component of the repressive nuclear chromatin remodeling NoRC complex, from the 
rDNA. Pharmacological inhibition of rRNA synthesis by the small molecule CX-5461 reduced 
the invasive capacity of cells in vitro, which correlated with a decrease in mesenchymal 
proteins, together confirming an important role of de novo ribosome biogenesis in EMT. In 
accordance with previous literature that have shown association of the mTORC2 complex with 
ribosomes, expression of Rictor, a mTORC2 complex component, was found to be induced in 
the nucleolus during EMT. This association of Rictor was observed to be rRNA dependent. 
Furthermore, inhibition of ribosome biogenesis significantly reduced the nucleolar expression 
of Rictor. Mouse models of metastatic breast cancer showed reduced tumor volume upon 
treatment with CX-5461 and a significant reduction in lung metastasis was observed. 
Interestingly, CX-5461 treated primary tumors were also more differentiated, as they had 
increased expression of cytokeratin 8/18, and were also Estrogen Receptor-alpha (ERα) 
positive and Rictor-negative, which altogether correlates with a less aggressive phenotype in 
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the MMTV-PyMT mouse tumor model. Further investigation into the driving mechanism of 
EMT by de novo ribosome biogenesis revealed pervasive changes in the translational control 
of gene expression program during EMT. This translational control during EMT was affected 
by inhibition of de novo rRNA synthesis by the Pol I assembly inhibitor, CX-5461. Though 
the transcriptional profiles remained the same, about 1478 genes were differentially expressed 
in the ribosome protected fragments during EMT. CX-5461 treatment blocked the 
upregulation of 185 and the downregulation of 179 translationally controlled genes. The 
expression of the translationally controlled genes post-TGFβ stimulation significantly 
overlapped with the translationally controlled genes affected by CX-5461. Interestingly, a 
translational reprogramming of the mTORC1 signaling cascade was observed during EMT, 
revealed by the downregulation of transcripts with short UTRs. This reprogramming was 
diminished by the inhibition of Pol I mediated rDNA transcription. These findings collectively 
provide compelling evidence that the EMT-associated ribosome biogenesis program, and by 
extension the ribosomes generated by this process, fuel the pro-migratory, pro-invasive gene 
expression program underpinning EMT and thus the mesenchymal phenotype. They also 
demonstrate compelling evidence that rRNA biogenesis plays a unique and targetable role in 
metastatic breast cancer development, progression and metastasis. 
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1 INTRODUCTION 
1.1 BREAST CANCER  
Globally, cancer is the second leading cause of death with about 9.6 million deaths reported in 
20181. Tumorigenesis occurs when normal cells acquire the ability to proliferate without any 
restriction in growth control, in addition to acquiring abnormal morphology and functional 
properties that can initiate a tumor2,3. The hallmarks of cancer were initially described by 
Hannan and Weinberg, and further revised a decade later2,4. Apart from having endless 
proliferative capacity, tumor cells also find ways to evade immune responses, induce tumor 
inflammation, promote angiogenesis and acquire resistance to cell death programs2,4. 
Furthermore, cancer cells also reprogram cellular metabolism, escape growth suppression, and 
activate cellular programs that drive invasion and metastasis along with genome instability2,4. 
A benign tumor does not have invasive abilities whereas a malignant tumor can invade and 
spread to distinct organs in the body2,5. The three most common cancers worldwide are lung, 
breast and colorectal cancer and ranks within top five in terms of mortality1. While all three 
cancers make up for about one third cancer incidences globally, lung and breast cancer account 
for the majority of new cancer diagnoses1. 
Breast cancer is the most commonly diagnosed cancer in women and is the primary cause of 
mortality in women, followed by lung cancer1. In Sweden, breast cancer is the second most 
common cancer, with about 8017 new diagnoses reported in 20186. The documented discovery 
of breast cancer dates back to about 3500 years ago where it was reported by Egyptians as 
‘tumors or ulcers of the breast’7. Normal breasts are composed of fat, connective tissue and 
glandular tissue called lobes7. A tumor that develops from the duct or lobular tissues of the 
breast is referred to as breast cancer7. These tumors contain highly proliferative cells due to 
genetic mutations, aberrant cell signaling, loss of tumor suppressors or over-activity of 
oncogenes8.   
1.1.1 Classification of breast cancer 
Breast cancer is classified based on histopathological type, molecular status, stage, and grade9. 
The classification of breast cancer based on its histopathological and molecular status are the 
estrogen receptor alpha (ERa), the progesterone receptor (PR), the epidermal growth factor 
receptor (EGFR) HER2/neu, the tumor suppressor p53, the BRCA gene (BReast CAncer gene), 
loss of heterozygosity (LOH) and contributes to the main molecular markers used in the 
diagnosis of breast cancer 10. The ERa and the PR status of a breast tumor will determine the 
type of primary line of therapy implemented in the clinic. ERa expression in breast tumors is 
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noted in about 70% of all breast tumors and denote the capacity of the tumors to respond to 
endocrine therapy11,12. PR is transcriptionally activated by ERa and is therefore correlated to 
the expression of ERa making it responsive to endocrine therapy13. HER2/neu is a growth 
promoting protein expressed in about 15% of the breast tumors14,15. The expression of HER2 
was initially considered to be a poor prognostic marker16,17. However, development of targeted 
therapy against HER2 led to the evolvement of HER2 as a prognostic marker16,17. Breast tumors 
lacking ERa, PR and HER2 expression are identified as triple negative breast cancer (TNBC) 
and are known for their aggressiveness and tumor relapse due to lack of therapy18. Ki67 is 
another critical marker used in the diagnosis of breast cancer19,20. This protein is associated 
with proliferating cells and utilized to assess the proliferation rate of tumor cells. Breast tumors 
with low expression of Ki67 correlates with a better probability of survival in patients19,20. 
The Nottingham histological grading system or the Elston Ellis grade system is used to classify 
breast tumors based on their morphological and cytological validation21. In this system, breast 
cancers are classified as grades I to III based on the aggressiveness of the tumor21. Mitotic 
count, nuclear polymorphism and tubule formation are the main factors assessed by the 
pathologist21. Grade I breast cancers are low-grade tumors that are non-invasive with slow 
growth rates and are well differentiated22. Grade II tumors are of moderate aggressiveness with 
abnormally looking/dedifferentiated cells with slightly higher proliferation rate22. Grade III are 
high grade tumors with poor differentiation and high proliferation rates with chances of 
metastasis23. 
Breast cancer can also be classified based on the TNM (Tumor, Node, Metastasis) system, 
depending on 1) primary tumor characteristics 2) if the cells have spread to lymph nodes and 
3) if metastases are found24. This gives rise to a five staged scale which reflects the severity of 
the disease, starting from stage 0 which is the non-invasive ductal carcinoma in situ and 
proceeds through stages I to IV denoting invasive breast cancer24. Stage 0 is when the breast 
cancer is non-invasive24. Stage I with sub-stages A and B, is when the tumor is less than 2 
centimeters and has not spread beyond the breast itself even though it is invasive or if the tumor 
cells are present in the nearby lymph nodes with an absence of a primary tumor in the breast24. 
Stage II tumors (with sub-stages A and B) are invasive and have spread to the nearby and 
auxiliary lymph nodes with tumor size ranging from less than 2 centimeters to 5 centimetres24. 
Stage IV tumors are those that have metastasized to distant organs24,25.  
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1.1.2 Non-invasive and invasive breast cancer 
The majority of breast cancer arises from the epithelial lining of the duct26 whereas tumors 
arising from the lobes constitute about 10-15%9,26. If the tumor cells are still confined in the 
ducts or lobules, the breast cancer is classified as non-invasive and benign9,27. The most 
common non-invasive breast tumor is ductal carcinoma in situ (DCIS), which is a premalignant 
lesion that can be further classified into low, intermediate and high grade based on their nuclear 
polymorphism and cellular attributes28. The lobular carcinoma in situ (LCIS) is the second most 
common type of non-invasive breast tumor and is often considered as a precursor of invasive 
carcinoma progression29 (Figure 1). 
 
Figure 1. Schematic demonstrating sub-breast tissue origins of breast cancer and 
progression towards aggressiveness  
Invasive malignant breast tumors have acquired the capacity to invade surrounding tissues and 
form secondary tumors, i.e., metastases in distant organs27. Invasive carcinoma of no special 
type (NST) is the most frequent type of invasive breast cancer and 80% of invasive carcinomas 
belong to this classification (this type was previously known as ductal carcinoma not otherwise 
specified)27. The second most common invasive breast cancer is invasive lobular carcinoma 
(ILC) and constitutes about 10% of the all invasive breast cancers27.  
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As a breast tumor is relatively easy to surgically remove from the primary location, the invasion 
and metastasis formed by malignant tumor cells are the cause of over 90% of all cancer-related 
deaths 30,31. Around 15% of patients with breast cancer develop metastases to distant sites in 
less than 3 years from diagnosis, though development of metastasis after 10 years of diagnosis 
also occurs32. Invasive breast cancer cells can disseminate and spread to distant sites forming 
metastasis most commonly in the lung, bone and liver30,31. Metastasis formation is a multistep 
cascade where the cancer cells invade surrounding tissues and enter the lymphatic or blood 
stream after acquiring invasive and migratory abilities33. These cells then form a secondary 
tumor at the metastatic site after extravasating through the endothelium33. A critical mechanism 
by which breast cancer cells acquire invasive ability is through epithelial-to-mesenchymal 
Transition (EMT), a cellular program that enables cells to leave the primary tissue34.  
1.2 EPITHELIAL–MESENCHYMAL TRANSITION 
Epithelial-Mesenchymal Transition (EMT) is a physiological process known for its 
indispensable role in implantation, embryogenesis and organ development35–37. EMT is the 
process in which epithelial cells undergo biochemical and physical changes to acquire a 
mesenchymal phenotype38. Epithelial cells are non-mobile and adhere to one another and to 
the basal membrane38. However, mesenchymal cells have the capacity to migrate and invade 
due to the loss of cell adhesion, remodeling of the cytoskeleton and the expression of 
matrix metalloproteinases (MMP), which are  capable of degrading the extracellular matrix38. 
In embryogenesis during gastrulation, EMT drives the separation of mesendoderm into 
mesoderm and endoderm in the primitive streak of the epiblast layer35–37. Mesoderm formed in 
between the epiblast and hypoblast layers then gives rise to the primary mesenchyme35–37. 
Moreover, EMT plays an important role in various pathological processes such as organ 
fibrosis and tumor invasiveness38.  The role of EMT in organ fibrosis, e.g. kidney, is fairly well 
understood. Expression of fibroblast specific protein (FSP1) in the tubular epithelial cells 
correlates with EMT in kidney fibrosis34,39. These FSP1+ epithelial cells that acquire partial 
mesenchymal signatures, migrate to the interstitium of the kidney through the damaged 
basement membrane where they accumulate to gain a fibroblast phenotype after losing their 
epithelial signature completely34,39. 
Another important pathological implication of EMT is its role in tumor metastasis34,39. 
Although cell proliferation is the main hallmark of epithelial cancers, EMT has been implicated 
in the mechanisms leading to formation of secondary tumors at distant sites39. By enabling cell 
migration, EMT has been suggested to be the first step of the metastatic cascade40. 
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A main characteristic of cancer cells undergoing EMT is that they lose the expression of the 
adhesion protein, E-cadherin. Regulation of the E-box elements in the E-cadherin promoter by 
the EMT associated transcription factors like Snail1, Snail2 and Twist leads to its 
transcriptional repression. Zeb1, 2 and basic helix-loop-helix (bHLH) factors also bind the E-
cadherin promoter during EMT and represses its expression. Gain of mesenchymal proteins 
like Vimentin and N-cadherin are also observed during EMT. Induction of EMT requires 
coordination of many signaling pathways, which results in elevated expression of main EMT 
transcriptional regulators, Snail1 and Twist41. 
The Transforming growth factor beta (TGFb) signaling pathway is one of the main inducers of 
EMT, which acts through subcellular signaling proteins known as Smads, which transduce 
signals from the cell surface to the cell nuclei41. In co-operation with TGFb, the RAS pathway 
has also been shown to drive EMT, by reducing cell proliferation through Smad3 activation42. 
Additionally, the Wnt signaling pathway can induce EMT through its canonical signaling 
cascade wherein b-catenin is stabilized by glycogen synthase kinase-3 beta (GSK3β) 
inhibition42. β-catenin then translocate to the nucleus and regulates various transcription factors 
including expression of Snail142. Hypoxia can trigger EMT through stabilization of HIF-1a, 
which in turn leads to the activation of Twist and Snail1 at the onset of EMT42. Transcriptional 
regulators of EMT work by both induction and repression43. Snail family primarily acts as 
repressors however recent literature also indicates that Snail1 can act as an activator43. Snail 
family consists of zinc-finger transcription factors which utilizes zinc to bind to DNA and 
regulates EMT both during development and tumor progression and metastasis45. Snail1 is 
shown to associate with Smad3 and Smad4 to regulate TGFb induced EMT44. Tight junctional 
proteins like Claudin and Occludin are also repressed by Snail1 during EMT46. Snail1 also 
plays a role in the degradation of extra cellular matrix (ECM) which is mediated by matrix 
metallo-proteinases (MMPs)45,47. Snail1 contributes to the acquisition of invasive ability during 
EMT by contributing to cytoskeletal changes by upregulating RhoB and thereby modulating 
cell shape45,47. Snail1 is also involved in the regulation of cell cycle progression by halting cells 
at the G1/S transition as well as conferring resistance to cell death48. This is mediated by 
downregulating Cyclin D2 and inducing p21/Cip148. Snail1 is activated and regulated by a 
number of signal transduction pathways including TGFβ, VEGF, EGF, FGF, HIF, WNT and 
NOTCH47,49. Transcriptional regulators of EMT with activating roles are AP-1, SP-1, NFKb 
factors and b-catenin, that induce the expression of mesenchymal genes like 
Vimentin50,51(Figure 2).  
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Importantly, EMT is also thought to promote therapeutic resistance, which represents a major 
challenge for effective treatment of metastatic breast cancer52,53. Hence, further understanding 
and characterization of the EMT is essential to be able to design novel cancer treatments aiming 
to inhibit metastasis52,53. One of the main strategies to target EMT has been to interfere with 
the signaling cascade responsible for the initiation of EMT54,55. This, however, might not be a 
useful intervention in the case when the metastatic process has already been initiated54,55. 
Therefore, targeting the mesenchymal phenotype and prevention of mesenchymal-to-epithelial 
transition (MET), a process where the disseminated cells acquire ‘epithelial-like’ phenotype 
required to form secondary tumors, seems equally important and should be considered as an 
effective alternative strategy. 
 
Figure 2. Schematic showing the process of epithelial-mesenchymal transition 
1.2.1 The TGFb  signaling pathway 
A principal regulator of EMT is TGFβ,  which is a multifunctional cytokine found in all 
multicellular organisms and is conserved throughout evolution56. The TGFβ  superfamily is 
comprised of TGFβs, activins, inhibins, bone morphogenetic proteins (BMPs), anti-müllerian 
hormone (AMH) as well as growth and differentiation factors (GDFs)56. The TGFβ family 
members are important regulators of several critical cellular processes like cell proliferation, 
differentiation, migration, invasion, and survival56,57. They are also involved in the regulation 
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of physiological processes, including embryonic development, EMT, extra-cellular matrix 
remodeling, angiogenesis, wound healing and immunosuppression56,57. Members of this 
superfamily are overexpressed in cancer, fibrosis and inflammation, where they affect cell 
growth, shape and migration thereby driving the disease progression58. 
The vertebrate genome encodes 30 ligands that belong to the TGFβ superfamily59. Abnormal 
expression of these ligands leads to developmental defects and progression of human 
diseases60. TGFβ1, TGFβ2 and TGFβ3 are the homologous isoforms of TGFβ in humans. 
These isoforms all signal in a similar manner and share the same receptor complex but differ 
in expression levels depending on the tissue in which they are expressed61. TGFβ ligands are 
initially produced as an inactive precursor and contained in a complex called the large latent 
complex (LLC). The LLC interacts with the latency-associated peptide (LAP) and a latent 
TGFβ-binding protein (LTBP) as a homo dimer62,63. In order for the TGFβ precursor to become 
activated, the LLC must be released from the extracellular matrix (ECM) leading to the 
subsequent release of TGFβ, making it available for binding to its receptors and for signaling. 
This release is mediated by the proteolysis of LAP62,63 which in turn is facilitated through a 
number of different TGFβ activators, including MMP2 and MMP9 and thrombospondin 1 
(THBS1)62,63. Proteolytic cleavage, increased interaction with integrins and pH changes can 
also activate latent TGFβ62,63. 
Once released from its inactive precursor state, TGFβ ligands are able to bind to the TGFβ 
receptor and initiate signaling64. Two main types of TGFβ receptors exists in humans: type I 
and type II receptors. Both of these receptors are serine/threonine kinase receptors that share 
related transmembrane regions and form a heterodimeric complex to enable TGFβ signaling64. 
The TGFβ family consists of seven type I receptors also called the activin receptor-like kinases 
(ALKs) and five type II receptors62,64. These receptors have different affinities for different 
ligands of the TGFβ superfamily64. For example, BMPs bind strongly to type I receptors and 
only weakly to type II receptors. Interestingly, the highest affinity of BMPs is seen in the 
combination of both receptors together64.  
After the ligand has bound the TGFβ receptor, the activation of TGFβ signaling is achieved 
either by the canonical pathway through Smads or by non-canonical pathway that is 
independent of Smads. These pathways can occur simultaneously64. Common Smads (Co-
Smad), receptor Smads (R-Smads) and inhibitory Smads (I-Smads) are the three classifications 
of Smads65. During Smad dependent signaling, the R-Smads (Smad1,2,3,5) associates with Co-
Smad (Smad4) and is translocated into the nucleus to activate or repress gene transcription 
depending on its binding partner65. Negative regulation of the TGFβ pathway is mediated by 
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Smad6 and Smad7 (I-Smads)65. PI3K-AKT, p38, RAS/ERK and JNK are non-Smad dependent 
signaling pathways mediated by TGFβ receptors66. The TGFβ signal transduction pathway has 
a dual role in cancer, exerting both tumor-suppressor and oncogenic signals through different 
factors which depends on the cellular context67. For example, TGFβ signaling has been shown 
to have a tumor suppressor effect during initial stages of the tumorigenesis process, and 
oncogenic effects as the cancer progresses, like promoting EMT67 (Figure 3).  
 
Figure 3. Diagrammatic illustration of TGF-b signal transduction pathway 
1.2.2 The Wnt signaling pathway 
The Wnt pathway is a highly evolutionary conserved signaling pathway that regulate critical 
cellular processes during development and tissue homeostasis, which frequently is 
dysregulated in human diseases. The Wnt proteins encoded by the Wnt genes (19 in mouse and 
human, 7 in Drosophila and 5 in C. elegans) act as ligands for the cell surface Frizzled receptors 
(Fzd), which initiates signaling that regulate a wide range of developmental functions including 
proliferation, migration, cell fate determination, cell polarity and stem cell maintenance 68. The 
first Wnt gene was isolated in 1982 from mouse mammary tumor and was named int-1 (mouse 
mammary tumor integration site-1)69. It was subsequently discovered that the int-1 gene is 
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conserved across multiple species, with high similarity to the Drosophila wingless gene wg, 
which led to the name Wnt by combining wg and int70.  
Figure 4. Diagrammatic illustration of canonical Wnt signaling pathway 
Wnt signals through both b-catenin dependent (canonical) and b-catenin independent (non-
canonical) pathways70. The canonical pathway, which mainly regulates cell proliferation, self-
renewal, homeostasis and embryonic development, operates through b-catenin, which is 
present in both cytoplasm and adherent junctions of the cytoskeleton70,71(Figure 4). When the 
Wnt pathway is inactive, cytoplasmic b-catenin is continuously phosphorylated and degraded 
by a destruction complex, composed of Axin, the tumor suppressor Adenomatous polyposis 
coli (APC), GSK-3b and Casein kinase 1 (CK1)72. When Wnt/b-catenin pathway is activated, 
Wnts bind to the Fzd receptors and low-density lipoprotein receptor related protein 5/6 
(LRP5/6) resulting in the translocation of the scaffold protein Dishevelled (Dvl) from 
cytoplasm to plasma membrane to interact with Fzd72. The Axin/GSK-3b complex is then 
sequestered to plasma membrane and the GSK-3b and CK1 kinase phosphorylates LRP5/6 
resulting in the inhibition of GSK-3b73. This in turn results in the accumulation of non-
phosphorylated, stabilized b-catenin in the cytoplasm, which subsequently can translocate to 
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the nucleus and engage in transcriptional regulation of Wnt target genes74,75. Wnt target genes 
include cyclin D174,75.  
Figure 5. Diagrammatic illustration of non-canonical Wnt signaling pathway 
The b-catenin-independent Wnt-signaling pathways (non-canonical) are less characterized 
than the canonical pathway and is initiated by Wnt11 and Wnt5a-binding to various receptors 
including ROR276(Figure 5). This pathway mainly regulates cell polarity, migration, motility 
and has been most studied in planar cell polarity (PCP) and intracellular calcium (Ca2+) 
cascades70. In PCP, Wnt ligands bind to the Fzd independent of LRP and activates the PCP 
pathway, which is responsible for cell polarity and movement during neural crest migration in 
embryos77. In the Wnt-mediated Ca2+ cascades, heterotrimeric G-proteins are downstream of 
Wnt-Fzd signaling, leading to an increase in intracellular concentration of Ca2+. This Wnt-
mediated Ca2+ cascade also requires the activation of  phospholipase C (PLC), which triggers 
diacylglycerol (DAG) and inositol triphosphate 3 (IP3) synthesis, ultimately stimulating protein 
kinase C (PKC) and calmodulin-dependent protein kinases (CaMK)78. 
Mis-regulation of the canonical Wnt pathway has been widely associated with breast cancer 
development and activation of processes like cell proliferation, EMT and metastasis have been 
observed68,76,79. Particularly, in triple negative breast cancers, induction of canonical Wnt 
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signaling is observed, which correlates with a poor prognosis80. In contrast, the role of non-
canonical Wnt signaling in cancer remains controversial as it has been suggested to exert both 
tumor suppressive and oncogenic effects. Non-canonical Wnts have been implicated to drive 
osteosarcoma81 and epithelial-mesenchymal transition in melanomas by activating PKC82. 
However,  downregulation of non-canonical Wnt5a signaling has also been demonstrated in a 
wide range of cancers like neuroblastoma, breast cancer, leukemia and colorectal cancer83. For 
example, Liu et al demonstrated that Wnt5a is frequently lost in hepatocellular carcinoma, 
suggesting a potential tumor suppressive role of this ligand84. Similarly, non-canonical Wnt 
signaling has been propsed to exert a tumor suppressive effect in breast cancer 85. Thus, the 
role of Wnt signaling in development and disease is highly complex and varies depending on 
the cellular context74  and needs further characterization.  
1.2.3 The Notch signaling pathway 
The Notch signaling pathway is an evolutionarily conserved cellular signaling pathway 
necessary for cell homeostasis through proliferation, apoptosis, cell fate specification, 
angiogenesis and homeostasis86. In vertebrates, the Notch signaling pathway encompasses four 
Notch receptors (Notch1, Notch2, Notch3, Notch4) and five ligands (Jagged1, Jagged2, 
Deltalike1, Deltalike3, Deltalike4). The Notch pathway is activated when a Notch ligand 
activates a receptor expressed on juxtaposed cells87. This activation is followed by a series of 
A Disintegrin and Metalloprotease (ADAM) and gamma-secretase dependent cleavages of the 
receptor, which results in the formation of an intracellular part of the Notch receptor, named 
the Notch intracellular domain (NICD)88. This intracellular fragment then translocates to the 
nucleus where it forms a complex with the transcription factor CSL (RBPJk), co-activators 
mastermindlike 1 (MAML1) and histone acetyl transferase (p300/CBP) and activates 
downstream target genes. These genes includes the Notch like hairy enhancer of split (Hes), 
Hes-related repressor protein (Herp), p21 and Myc88.  
Aberrant signaling of the Notch pathway has been identified in the pathology of several 
diseases, including cancer89. For example, dysregulated Notch signaling is highly implicated 
to drive certain hematopoietic cancers and solid tumors, including breast cancer90–92. Moreover, 
dysregulated Notch signaling have been found to drive EMT through hypoxia and estrogen 
signals from the microenvironment93. During hypoxia-induced EMT, NICD is stabilized by the 
hypoxia-induced transcription factor HIF-1a, resulting in increased Snail1 transcription94. In 
addition to this mechanism, HIF-1a can activate Snail1 and Snail2 by binding directly to the 
Hes1 and His2 promoters along with the Notch co-activator MAML1 during hypoxia95. 
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1.3 BREAST CANCER TREATMENT STRATEGIES 
Breast cancer is a heterogenous disease with multiple molecular subtypes. The ERa positive 
breast tumors makes up about 70% of all breast tumors11. Hence, endocrine therapy strategies 
targeting estrogen signaling has been critical in treating breast cancer for more than a century96. 
Competitive inhibitors of the ER binding sites have been in use since 1970s96. Downstream 
estrogen activity inhibitors like aromatase inhibitors includes exesmestane and anastrozole, 
prevents the catalyzation of androgen hormone into estrogens97,98. Fulvestrant, an ER 
antagonist which aids in degrading ER, has also been developed99,100.  One of the primary lines 
of breast cancer therapy of ERa positive breast cancers is Tamoxifen, an estrogen receptor 
modulator (SERM) that has been shown to significantly increase the overall survival in 
patients96. The ‘HER2 enriched’ tumors that form about 20% of the breast tumors are treated 
with drugs like lapatinib, trastuzumab and pertuzumab that directly target the HER2 protein 
expression101. HER2 functions are mainly mediated through pathways like PI3K-AKT and 
RAS-MAPK, so targeting these pathways are potent therapeutic avenues102,103. PI3K mutations 
are found in over 20% of the breast cancer patients104. mTOR (mammalian target of rapamycin) 
is activated by phosphorylated AKT leading to cell proliferation and increased protein 
synthesis, making mTOR inhibition a therapeutic target105. Buparlisib is a PI3K-AKT inhibitor 
currently used in clinical trials. Everolimus, an mTOR inhibitor has already been approved for 
treatment of metastatic breast cancer in combination with exemestane, an endocrine therapy 
which have been demonstrated to result in an increase in the progression-free survival of the 
patients106,107. 
Chemotherapy is a treatment option when the endocrine targeting options have been exhausted 
or if immediate response is required108. Pre-operative chemotherapy has been shown to have 
equal outcome in regards to progression free survival and overall survival as compared to 
postoperative chemotherapy108. Anthracyclines are active chemotherapeutic agents that work 
by inducing apoptosis and inhibiting DNA and RNA synthesis whereas taxanes inhibit cell 
proliferation and function by stabilization of microtubules109. Anthracyclines and taxanes, in 
combination or in series are administered as current standard of care in early breast cancer108. 
Chemotherapy is considered preferable for TNBC and in HER2 positive patients following 
neoadjuvant therapy and surgical intervention108. The TNBC and HER2 positive subtypes 
show better response with patient outcome in relation to pathological response108.  
Ribosome biogenesis and dysregulation of its associated factors are frequently encountered in 
breast cancer110. Induction of ribosome biogenesis is observed in TNBC and inactivation of 
ribosomal protein RPL5-uL18  has been observed in 34% of breast cancers110. RPL5-uL18 has 
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a critical role in MDM2 inactivation together with 5S rRNA110. Highly proliferative, BRCA1/2 
deficient tumors have been shown to be specifically sensitive to RNA Polymerase I (Pol I) 
inhibitors like CX-5461 and CX-3543 that inhibit the initiation of ribosome biogenesis by 
targeting the Pol I complex. The suggested mechanism for this is that these tumors cells have 
a decreased ability to repair DNA damage caused by blockage of replication forks by the 
ribosome biogenesis inhibitors111. This is in turn suggested to be due to G4 stabilization caused 
by the Pol I inhibitors111. CX-5461 is currently under advanced phase I clinical trials in Canada 
(NCT02719977)111. The trial includes breast cancer patients carrying the BRCA1/2 deficient 
tumors111. Taken together, targeting of ribosome biogenesis may therefore represent a novel 
potent therapeutic target which is distinct from ionizing radiation and conventional 
chemotherapy. There is therefore, a need for more thorough biological characterization of 
ribosome biogenesis in tumor progression to know how we can better target this complex and 
metabolic pathway. 
1.4 RIBOSOME BIOGENESIS AND ITS REGULATION 
Ribosomes are complex molecular machines that are responsible for protein translation112. 
They are essential for cellular growth and proliferation and the target of many regulatory 
signaling pathways112. Ribosomes play a central role during normal growth, development and 
defects in ribosome synthesis will cause deleterious effects on cell physiology113. The 
production of new ribosomes, known as ribosomal biogenesis, is a complex process involving 
transcription of ribosomal RNA (rRNA) genes by RNA Polymerases (Pol I and Pol III), 
cleavage of the pre-rRNA transcripts, followed by rRNA modifications (methylation and  
pseudouridylation114)  and assembly with ribosomal proteins (rp) synthesized by RNA 
Polymerase II (Pol II), to form the mature ribosomes115(Figure 6). The ribosome backbone 
consists of rRNA which is transcribed in the nucleolus, the most prominent structure in the 
nucleus116. The human genome is estimated to have on average 200-400 copies of rRNA genes 
while there are individuals that encompass more than 1000 copies that are transcribed with high 
efficiency to generate sufficient ribosomes to fulfil the demands of proliferating cell115.  
rRNA biogenesis starts with that ribosomal DNA (rDNA) is transcribed by Pol I as a large 47S 
rRNA transcript in humans, and 45S in mice117. This transcript is further cleaved into 18S, 5.8S 
and 28S transcripts, which form the rRNA backbone of the ribosomes along with the 5S 
transcript synthesized by Pol III117. rDNA transcription is initiated by the assembly of a multi-
protein complex at the rDNA promoter along with various auxiliary proteins117. Specifically, 
the upstream Binding factor (UBF) and the Selectivity Factor 1 (SL1) complex are the main 
Pol I specific components that act synergistically to form the pre-initiation complex necessary 
 22 
for initiation of rDNA transcription117. UBF is a DNA binding protein that recognizes both 
DNA Control elements, CORE and Upstream control element, UCE117. UBF is the first Pol I 
specific transcription factor identified and has repeated regions of 85 amino acids homologous 
to high mobility group proteins (HMG boxes). This protein bind promoters and facilitate 
bending in DNA to activate transcription117. In addition, these proteins have been suggested to 
activate chromatin throughout the rDNA gene cassette to facilitate transcription elongation, 
since UBF and SL1 are found not only at the promoter site but also along the transcribed 
region117. Another known important regulator of rDNA transcription is the SL1 complex, 
which exists as a TBP-TAF1 complex in cells118. There are three different TAFs (TBP-
associated factor) named according to their respective molecular mass of 48 (TAFI48), 63 
(TAFI63) and 110 kDa (TAFI110)119,120. Together, the SL1 complex and Pol I can initiate basal 
transcriptional activity of the rDNA promoter, but for full activation of rDNA transcription, 
UBF binding is also needed121. Accordingly, polymorphisms that destroy the association of 
UBF with either the rDNA promoter or SL1 deteriorate the assembly of the Pol I complex and 
transcription activity of Pol I122–124. Other examples of known regulators of rDNA transcription 
are enhancer I binding factor (EIBF), which interacts with the proximal promoter and the 
enhancer region125,126, Core promoter-binding factor (CPBF), which binds to the promoter and 
increases transcription efficiency by interacting with EIBF127,128, and Topoisomerase I, which 
facilitates rRNA synthesis through DNA unwinding117.  
Figure 6. Illustration of the process of ribosome biogenesis 
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Post-translational modifications and in particular phosphorylation of the auxiliary proteins 
involved in ribosomal biogenesis play an important role in the regulation of rDNA transcription 
129,130. For example, the serine residues at the carboxy terminal activation sites of UBF have 
been found to be subjected to phosphorylation129,130, which is essential for SL1 recruitment131 
and as such increases rDNA transcription activity. Therefore, increased UBF phosphorylation 
is observed when rDNA transcription is enhanced, for example, when quiescent cells are 
stimulated with serum129,130, or during phytohemagglutinin induced lymphocyte stimulation132. 
SL1 is also known to be regulated by phosphorylation133 and  repression of rDNA transcription 
due to phosphorylation of SL1 is observed during mitosis117. In addition to phosphorylation, 
protein acetylation also positively regulates rDNA transcription117, as Muth et al and Pelletier 
et al showed that UBF and SL1 subunits are acetylated in vivo during rDNA transcription134. 
Ribosome biogenesis is regulated by evolutionary conserved signaling pathways, including 
PI3-AKT, mTOR, MYC, and p53-Rb. Changes in nucleolar architecture and its association to 
cancer progression have been studied since the late 19th century116. Increased size of nucleolar 
organizing regions (NORs), which are visualized by silver stain, has been a classic feature of 
cancer cells and has been suggested as a potent prognostic factor135. The regulation of 
biogenesis by known oncogenes and tumor suppressors (mTOR, MYC, and p53-Rb) 
underlines the importance of future studies on the impact of this process on cancer initiation 
and progression110. 
1.4.1 The PI3K-AKT-mTOR signaling pathway  
The PI3K-AKT-mTOR signaling pathway has been extensively studied due to its engagement 
in cellular processes like cell growth and proliferation which is ultimately linked to its role in 
regulating ribosome biogenesis136,137. The pathway consists of the three conserved kinases; 
mTOR, AKT (protein kinase B) and PI3K (phosphoinositide 3-kinase)136,137.  AKT exerts its 
role in cell survival by phosphorylating a variety of substrates and is a downstream effector of 
the PI3K transduction cascade that modulates ribosome biogenesis. PI3K mediated activation 
of ribosome biogenesis is mediated by an induction of Pol I and Pol III mediated 
transcription138. Out of the many substrates of AKT that has been studied, the most important 
and well characterized substrate being linked to ribosome biogenesis is the mTORC1/2 
complex139,140. mTOR is a kinase consisting of two complexes; the mTOR complex 
1(mTORC1) or the mTOR complex 2 (mTORC2)139. The mTORC1 and mTORC2 complexes 
have common protein members; the mTOR, mLST8 or GbL (G protein b subunit like) and 
Deptor which associates with mTOR in the DEP domain139. The mTORC1 complex consists 
of Raptor whereas the mTORC2 complex consists of PRR5 (Proline rich protein 5), Sin1 
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(MAPKAP1) and Rictor 139. mTORC2 is actively involved in cytoskeleton remodeling and in 
the regulation of ribosome biogenesis by the physical association of mTORC2 with the mature 
ribosome whereas mTORC1 is majorly involved in regulation of ribosome biogenesis and 
translation in proliferating cells139,141(Figure 7).  
 
Figure 7. Schematic representation of mTORC regulation of ribosome biogenesis and 
translation 
A role of mTOR in rDNA transcription has been documented where mTOR is involved in the 
activation of UBF and TIF-1A. mTOR regulates the phosphorylation of UBF at the C-terminus 
through ribosomal protein S6 kinase (S6K)142. Pol III dependent 5s rRNA transcription is also 
activated after recruitment of mTOR to its promoter resulting in the phosphorylation of MAF1 
which inhibits TF-IIIB complex assembly and transcription initiation143. Further, mTORC1-
AKT mediated phosphorylation of the transcriptional repressor MAD1 releases MAD1 from 
the MYC-MAX complex which can then engage in rDNA transcription144.  
1.4.2 Role of Protein kinase CK2 in ribosome biogenesis 
Protein kinase CK2 that plays a critical role in tumor development, cell cycle progression, 
regulation of oncogenes and tumor suppressors145. It is a serine threonine kinase and regulates 
ribosome biogenesis by modulating the interaction of UBF, SL1/TIF1B, TIF-1A, NPM and 
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NCL with the Pol I complex through phosphorylation thereby affecting rDNA 
transcription145,146. CK2 mediated phosphorylation leads to the stabilization of UBF- 
SL1/TIF1B complex as well as its binding to rDNA147. In addition, CK2 also binds to the 
initiation inducing sub-component of Pol I, Pol Ib118. 
1.4.3 The MAPK signaling pathway 
Mitogen activated protein kinases (MAPK) signaling pathway are known to regulate ribosome 
biogenesis through the two critical factors involved in Pol I mediated rDNA transcription, UBF 
and TIF-1A148,149. The MAPK family member extracellular signal-regulated kinase (ERK),  
promotes UBF-DNA interaction by modulating its phosphorylation leading to increased Pol I 
engagement at the promoter150. In addition, ribosomal S6 kinase, another member of the MAPK 
family, is involved in the phosphorylation of TIF-1A contributing to regulation of ribosome 
biogenesis148,150. 
1.4.4 Role of MYC in ribosome biogenesis 
MYC is a proto-oncogene that regulates all three RNA polymerases and is associated with 
regulation of at least 15% of the genome151. Three genes belong to the MYC family: MYC, 
MYCN and MYCL1, which all are transcription factors regulating the expression of genes 
involved in cell growth, metabolism, apoptosis, DNA repair, angiogenesis and protein 
synthesis152. MYC has been shown to repress and activate genes by chromatin remodeling. 
MYC’s role in chromatin remodeling, transcriptional changes and ribosome biogenesis plays 
a significant role in cell physiology like proliferation, senescence and differentiation152.  
The role of MYC in regulation of ribosome biogenesis is well documented151. MYC, for 
example, plays a direct role in influencing rDNA transcription by modulating recruitment of 
Pol I complex components (UBF and SL1) to the rDNA promoter151. Moreover, UBF 
expression is controlled by MYC in Pol II dependent manner. Regulation by increased binding 
of Pol I complex is executed through MYC binding to TBP and TAFs of SL1151. Additionally, 
MYC enhances rDNA transcription by increasing the recruitment of co-factors and remodeling 
of the chromatin at rDNA loci151.  
The role of MYC in regulating the transcription of Pol III transcribed 5S rRNA is through 
TFIIIB and by expression of ribosomal proteins transcribed by Pol II further supports MYC’s 
key regulatory role in ribosome biogenesis and as a pan RNA polymerase regulator151,153. 
Proteins involved in the processing of rRNA like fibrillarin (FBL), nucleolin (NCL), 
nucleophosmin (NPM), block of proliferation1 (BOP1), dyskerin (DKC), nuclear protein 56 
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(NOP56) are also regulated by MYC154. NPM1 is involved in direct regulation of ribosome 
biogenesis by direct association with MYC at target promoters155. NPM1 is a nuclear 
phosphoprotein which positively regulates ribosome biogenesis and contributes to protein 
synthesis155. It also regulates ribosomal protein nuclear import, ribosomal subunit export and 
assembly of ribosomes156. 
1.4.5 Regulation of ribosome biogenesis during cell cycle  
Cell cycle regulators play a crucial role in the regulation of ribosome biogenesis since the 
balance between ribosome biogenesis and cell cycle progression is essential for normal cell 
survival and growth144. The retinoblastoma (Rb) tumor suppressor is the key G1 phase 
checkpoint regulator of cell cycle progression before entering into S phase157. When the cell is 
ready to divide, Rb gets phosphorylated, leading to its inactivation and hence allows cell cycle 
progression157. Rb in its unphosphorylated form regulates cell cycle progression by interacting 
with transcription factor E2F to activate downstream gene targets157. Rb is phosphorylated and  
inhibited in proliferating cells by cyclin-dependent kinases like CDK2, CDK4 and CDK6158. 
Hyper-phosphorylation of Rb leads to a loss in the activity of Rb by activation of these cyclin 
dependent kinases158. A direct link between ribosome biogenesis and cell cycle is that the 
hyper-phosphorylated, non-active form of Rb interacts with UBF which is a part of the Pol I 
complex to inhibit the synthesis of 47S transcript110. Similarly, synthesis of 5S rRNA is 
impaired by association of inactive Rb with  TF-IIIB of the Pol III complex110.  
Two other important regulator of rRNA biogenesis and the cell cycle is the p14/p19ARF (ARF), 
which is encoded by the CDKN2A gene and p53159,160. p53 is a major inducer of cycle arrest 
and/or apoptosis and is mutated in more than 50% of all human tumors, whereas ARF 
mutations are found in about 40% of the human tumors156,161. ARF represses ribosome 
biogenesis in a p53 independent manner by affecting rRNA processing by binding NPM1 and 
promoting degradation by ubiquitinylation162. NPM1 also associates with Mouse double 
minute 2 (MDM2) which is a E3 ubiquitin ligase responsible for the degradation of p53163. This 
association leads to the inhibition of MDM2 activity leading to the stabilization of p53 in the 
nucleus163. p53 regulates ribosomal biogenesis by binding to SL-1 and transcription factor IIIB 
(TFIIIB) interfering with the transcription of rRNAs, snoRNAs and tRNAs120,153. Moreover, 
the auto-regulation of p53, where it initiates the transcript synthesis upon MDM2 binding for 
degradation, is a checkpoint for ribosomal stress164,165. Like NPM1, nucleostemin (NS) also 
results in the stabilization of p53 by binding to MDM2166. Ribosomal proteins like RPL5, 
RPL11, RPL23, RPS3 and RPS7 bind directly to MDM2 thereby inhibiting p53164,165,167. 
Marechal et al co-immunoprecipitated RPL5 and 5S rRNA along with the p53-MDM2 
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complex, suggesting its role in the regulation of ribosome biogenesis or translation of cell cycle 
specific mRNAs168. It has been shown that ribosomal proteins not assembled into ribosomes 
activates p53 by binding to MDM2 and inhibiting it. RPS14 is found to inhibit CDK4/Cyclin 
D1 complex and activate Rb by inhibiting its phosphorylation leading to senescence and cell 
cycle arrest158. Pestov et al suggests that the cell cycle regulatory pathway might send cues that 
regulate ribosome biogenesis169. Collectively, these data show an intimate link between 
ribosome biogenesis and cell cycle regulation. 
1.5 TRANSLATIONAL MACHINERY AND ITS DYSREGULATION IN 
CANCER 
1.5.1 Translation Initiation 
The process of translation takes place through the three main stages of initiation, elongation, 
and termination170. The main factors involved in initiation are eukaryotic initiation factors (eIF) 
1,2,3,4,5 along with the ternary complex made of eIF2, GTP and Met-tRNAi171,172. These 
initiation factors aid in the formation of the 43S pre-initiation complex together with 40S 
ribosomal subunit, which then interacts with m7Gppp capped 5′ end of mRNA during 
initiation172. This loading of the 43S pre-initiation complex to the 5’ untranslated region (UTR) 
requires co-operation of co-factors like eIF4F, eIF4B and eIF4H. eIF4F consists of the DEAD-
box RNA helicase eIF4A and eIF4G. The latter binds the eIF4E, eIF4A, poly(A)-binding 
protein and eIF3 in addition to the cap binding protein eIF4E172,173. eIF4B and eIF4H plays a 
role in inducing the helicase activity of eIF4A174. eIF4E bound to eIF4F independent of its 5’ 
cap binding activity, also enhances the helicase activity of eIF4A175. The pre-initiation complex 
runs through the triplet codons entering the ribosome at P(peptidyl) decoding site 
complementary to the anticodon Met-tRNAi, checking its integrity downstream of 5’UTR172. 
eIF1 and eIF1A recognizes the start site (AUG) of the mRNA by modifying the mRNA-binding 
cleft structure172. The translation process is initiated when the 80S ribosomal unit, formed by 
the 60S ribosomal subunit and start codon complex is assembled on the mRNA after release of 
the initiation factors172. The A-site (aminoacyl) is then prepared to be filled with the 
complementary tRNA (aminoacyl) received by the 80S complex which leads to the first peptide 
bond synthesis172,176. 5′ 7-methylguanosine (m7G) cap independent translation of mRNAs are 
seen in some eukaryotes where the 40S subunit is recruited to the internal ribosome entry site 
(IRES), which is a cis-acting element situated at the 5’ UTR172. IRES trans-acting factors 
(ITAFs) are involved in the regulation of IRES and their interaction with the 40S subunit 
directs the initiation codon to the ribosomal P-site. IRES mediated translation is upregulated 
under stress conditions when cap dependent translation is inhibited177. Modulation of IRES 
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mediated translation is also dependent on the ribosome composition changes in addition to 
ITAF activity177. 
1.5.2 Translation elongation 
The two main factors involved in the execution of the translation elongation process are eEF1 
and eEF2, which are responsible for the delivery of aminoacyl tRNA to the A site of the 
ribosomes and for aiding ribosome translocation178. The GTP from the eEF1A- GTP complex 
is hydrolyzed upon codon matching after the aminoacyl tRNA delivery to the A site resulting 
in the release of eEF1A-GDP complex, that is then recycled by eEF1B179. Unphosphorylated 
eEF2 is mainly involved in ribosome translocation where the peptide is transferred from the A 
site to the P site of the translating ribosome179. eEF2 Kinase (eEF2K) can phosphorylate eEF2 
resulting in inhibition of its activity and potentially binding thereby perturbing the elongation 
process179. During elongation, the ribosomes move along the mRNA in a stop-and-go fashion 
and is not consistent, with various cis and trans factors influencing the ribosome speed along 
the mRNA173. 
1.5.3 Translation termination 
When the ribosomal A site encounters a stop codon on the RNA, translation termination occurs 
via the release of eRF1 and eRF3180,181. eRF1 is responsible for the recognition of the stop 
codon and the release of tRNA while eRF1 stimulates the release of peptide from the 
complex182. The 40S subunit is, in some cases, found to be associated with mRNA after a 
mature polypeptide has been released, which enables re-initiation of translation from a new 
start codon downstream of the previous stop codon180. Re-initiation during translation is 
observed in 3’UTRs which are upregulated during conditions of stress arising from nutrient 
starvation. A non-canonical initiation factor complex MCT-1/DENR is also implicated in the 
re-initiation process in addition to the standard factors183. 
1.5.4 Dysregulation of factors involved in translation in cancer 
Regulation of mRNA transcription has been widely studied in cancer. During recent years 
studies have revealed that mRNA transcript levels and proteins levels are not always mirroring 
each other and therefore highlights the importance of gene regulation at a translational level184. 
Importantly, the translation machinery components have also been found to be highly 
dysregulated in cancer185. The role of initiation factor eIF4E in tumorigenesis is well studied185. 
One study has demonstrated that increased expression of eIF4E results in increased translation 
of genes that induce tumorigenesis including the ones responsible for ribosome biogenesis, 
apoptosis, cell signaling, oxidative phosphorylation and nucleotide biosynthesis186. 
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Phosphorylation of eIF4E, which is carried out by the MNK1/2 serine/threonine kinases, is also 
associated with enhanced translation of tumor inducing mRNAs and is also critical for EMT187–
189. Upregulation of HuR (ELAV-like RNA-binding protein 1), one of the components required 
for eIF4E mRNA stability regulation in cancer, leads to induced eIF4E protein levels and is 
implicated in gene dysregulation at transcriptional and translational level by translational 
upregulation of specific tumorigenic mRNAs, HuR and eIF4E190. Another example is the 
modulation of translation process by the mTORC1 complex through regulation of eIF4F 
assembly191,192. Specific mRNA translation and global protein synthesis upregulation by 
mTORC1 is mediated downstream through activation of 4E-BPs and ribosomal protein S6 
kinases (S6Ks) 191–193. The phosphorylation of 4E-BP by mTORC1 plays a role in its binding 
competence with eIF4G for the eIF4E binding site, thereby, regulating the eIF4F complex 
formation191–193. The eIF4F complex is essential to recruit 40S ribosomal subunit required for 
CAP-dependent translation194. This recruitment is made to the mRNA’s  5′ N7-methyl 
guanosine CAP [m7G(5’)ppp(5’)N] in order to carry out CAP-dependent translation194.  CAP-
dependent translation starts off by the association of eIF4E to a modified guanosine called CAP 
at 5’ end of the mRNA and is facilitated by the phosphorylation of 4E-BP by mTORC1 which 
leads to the release of eIF4E to form a complex eIF4F along with eIF4G192,195. In the absence 
of phosphorylation by mTORC1, 4E-BP remains bound to eIF4E thereby dissociating it from 
eIF4G193. The activation of p70S6K through phosphorylation by mTORC1 also enhances 
CAP-dependent translation by phosphorylating PDCD4 and eIF4B193,196. The activity levels of 
the mTORC1 and mTORC2 complexes are regulated by mTOR through phosphorylation of its 
components. Another example is that cancer cells express higher levels of phosphorylated 
eIF2a, which induces the translation of mRNA genes specific for stress adaptation, resulting 
in increased survival of tumor cells197.  
Furthermore, structural features of mRNA like the 5’UTR and 3’UTR lengths and its stability 
contributes to its translational regulation and its association with miRNAs, initiation factors 
and RNA binding proteins198. These features are more commonly found in mRNAs coding for 
tumorigenesis and is tightly regulated at a translational level198. In addition to the length of the 
UTRs, the UTR associated mRNA elements also contributes to translational regulation. For 
instance, eIF4E mediated translation initiation of the 5’UTR of some mRNAs were preferred 
compared to the dependence on eIF4A198. The structural feature of some 5’UTRs associates 
with RNA binding proteins to regulate translation198. For example, during EMT, heterogenous 
ribonucleoprotein (HnRNP) E1 binds to TGFb-activated translation, BAT element located on 
3’UTR of specific mRNA transcripts important for EMT199,200. This results in the inhibition of 
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eEF1A1 dissociation from the A-site and thereby stopping elongation199,200. Elongation of these 
EMT regulating transcripts takes place upon TGFb induced phosphorylation of HnRNP E1 
which dissociates the BAT element199,200. 
Translation is also dysregulated in cancers at the level of elongation. Phosphorylation of 
elongation factor eEF2 by eEF2K plays a critical role in translation elongation regulation and 
is directly regulated by mTOR signaling201,202. eEF2K is downregulated in many cancers 
leading to continuous translation elongation of transcripts in tumor cells by induction of eEF2 
activation201,202. 
1.5.5 Specialized ribosomes 
Over the years, the conventional understanding of ribosomes as a static apparatus with only 
constitutive ability and non-regulatory functions has now been challenged by studies 
demonstrating ribosome heterogeneity203,204. Given that there are 80 ribosomal proteins, 
hundreds of ribosomes associated factors and several rRNA sequences, the ribosomes can be 
considered highly complex structures and almost per definition heterogenous203,204. Recent 
studies have showed that ribosomes can have specialized functions arising from variations in 
ribosomal proteins, post-translational modifications of ribosomal proteins and sequences of 
rRNA that make up the ribosomes203–207. More specialized translation by ribosomes can be 
attributed to its association to cis-acting elements with a specific mRNA subset. Specific 
ribosome associated factors can also lead to specific translation208. Examples of such factors 
are scaffold protein, protein kinase C (PKC) which associates with 40S subunit and its receptor 
RACK1 that interacts with various signaling molecules to make changes in the translation 
machinery208. Tissue specific allelic variants of rDNA genes in human and mice have also been 
found, though the functions of these variations remain unknown and to be functionally 
tested205. Heterogenous population of ribosomes in a single cell and its regulatory functions 
with regards to gene expression regulation and cell physiology are currently being 
discussed203,204. 
1.6 THERAPEUTIC POTENTIAL OF TARGETING RIBOSOME 
BIOGENESIS 
Given that increased ribosome biogenesis and protein synthesis have been implicated in cancer, 
targeting ribosomal biogenesis and the translation machinery represents an attractive 
therapeutic target. This notion is further underscored by recent evidences of genetic mutations 
in ribosomal proteins and the idea of ‘specialized ribosomes’204. Disruption of ribosome 
biogenesis by inhibiting Pol I mediated rDNA transcription can be achieved with various 
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compounds including actinomycin D and BMH-21209 (Table 1). Actinomycin D is a derivative 
of acridine, that intercalates into GC-rich regions of the rDNA genes and inhibits synthesis of 
rRNA by Pol I209. The rDNA promoter sequences are rich in G-quadraplex structures and 
compounds like CX-3543 and CX-5461 inhibits Pol I mediated rDNA transcription by binding 
to these quadraplex structures in proliferating cancer cells and prevents the association of 
Nucleolin (CX-3543) or SL-1 (CX-5461) to the promoter111. CX-5461 has been shown to have 
potent anti-tumor effect both in vitro and in vivo and is currently in clinical trial trials for 
hematological and breast cancer, making it the first Pol I inhibitor to enter into clinical trial111. 
This anti-cancer effect is thought to be mediated through both p53 dependent and p53 
independent mechanisms. It has further been suggested that CX-5461 hampers the DNA 
replication fork by stabilizing the G4 DNA, which has led to its application in BRCA1 and 
BRCA2 deficient tumors where homologous recombination is altered111. Furthermore, 
platinum drugs like phenanthriplatin and oxaliplatin have shown to inhibit rDNA transcription 
as their main mechanism of action rather than only inducing conventional DNA damaging 
activity209.  
Tumors with increased ribosome biogenesis might also be able to evade immune responses by 
upregulated expression of programmed death ligands 1/2 (PD-L1 and PD-L2)209. Signaling 
transduction pathways like PI3K-AKT-mTORC and RAS/ERK that regulate ribosome 
biogenesis are dysregulated in many tumors and can be targeted by ribosome biogenesis 
inhibitors for effective therapy. Combination therapy using Pol I inhibitor CX-5461 and 
inhibitors against PI3K-AKT-mTORC1 dependent ribosome biogenesis showed additive 
effects in Eµ-MYC lymphoma mice suggesting its potential, for example in MYC driven 
cancers210. Collectively, these data suggest that ribosome biogenesis is an important target in 
cancer and further understanding of ribosome biogenesis and the translation landscape in 
cancer may open up new avenues for treatment of aggressive cancers that currently lack 
effective therapy. 
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Table 1. Ribosome biogenesis inhibitors 
  
Drug Target Mode of action Reference 
Actinomycin D GC-rich duplex DNA Inhibits RNA Pol I-dependent 
transcription, promotes nucleolar 
disintegration 
(Scala et al., 2016) 
Avrainvillamide NPM1 Promotes NPM1 dissociation in 
nucleolus 
(Mukherjee et al., 
2015) 
Camptothecin Topoisomerase I Inhibits early rRNA processing, 
promotes nucleolar disintegration 
(Burger et al., 2010) 
Doxorubicin Topoisomerase II, forms 
DNA intercalation 
Inhibits RNA Pol I-dependent 
transcription 
(Burger et al., 2010) 
Flavopiridol CDKs Inhibits early rRNA processing, 
promotes nucleolar disintegration, 
downregulates RP expression 
(Erol et al., 2017), 
(Burger et al., 2010) 
Oxiliplatin Forms DNA cross-links, 
transcription-translation 
mechanisms 
Inhibits late rRNA processing (Bruno et al., 2017) 
CX-3543 rDNA G-quadruplexes Inhibits RNA Pol I-dependent 
transcription elongation, promotes 
nucleolin redistribution 
(Drygin et al., 2009) 
CX-5461 rDNA G-quadruplexes Inhibits RNA Pol I-dependent 
transcription initiation, promotes 
nucleolar disintegration 
(Bywater et al., 2012) 
5-Fluoroacil Thymidylate synthase, 
incorporation into 47S pre-
rRNA 
Inhibits late rRNA processing (Burger et al., 2010) 
MG-132 Proteasome Inhibits late rRNA processing (Burger et al., 2010) 
Mitomycin C 5’-CpG-3’ guanosine 
alkylation in DNA 
Inhibits RNA Pol I-dependent 
transcription, promotes nucleolar 
disintegration 
(Snodgrass, Collier, 
Coon, & Pritsos, 2010) 
Everolimus mTOR Inhibits rDNA transcription initiation (Devlin et al., 2016) 
BMH-21 rDNA GC-rich sequences Inhibits RNA Pol I assembly (Peltonen et al., 2014) 
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2 AIMS OF THE THESIS 
The main objective of the thesis was to study role of ribosome biogenesis during tumor growth, 
progression and metastasis. Specifically, we investigated the dynamics and epigenetic control 
of de novo rRNA biogenesis and translation control underpinning the EMT program. 
Specific aims of the thesis were the following: 
1. Determine the role and epigenetic control of de novo rRNA biogenesis during EMT 
2. Determine the role of Snail1in ribosome biogenesis during EMT 
3. Determine and uncover translation control during EMT as a mechanistic link to de novo 
rRNA induced EMT 
4. Determine the role of Wnt5a signaling in ribosome biogenesis in breast cancer 
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3 RESULTS  
3.1 PAPER I 
Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease 
Varsha Prakash*, Brittany B. Carson*, Jennifer M. Feenstra, Randall A. Dass, Petra Sekyrova, Ayuko 
Hoshino, Julian Petersen, Yuan Guo, Matthew M. Parks, Chad M. Kurylo, Jake E. Batchelder, Kristian 
Haller, Ayako Hashimoto, Helene Rundqivst, John S. Condeelis, C. David Allis, Denis Drygin, M. 
Angela Nieto, Michael Andäng, Piergiorgio Percipalle, Jonas Bergh, Igor Adameyko, Ann-Kristin 
Östlund Farrants, Johan Hartman, David Lyden, Kristian Pietras, Scott C. Blanchard, C. Theresa 
Vincent 
Induced rRNA synthesis is observed during EMT in vitro and in vivo 
The mouse mammary epithelial cell line, NMuMG, which undergoes EMT after 48h of TGFβ 
treatment was employed to study rRNA synthesis during EMT. EMT was confirmed by 
decreased expression of epithelial markers E-cadherin (cdh1) as detected by 
immunofluorescence. Loss of coxsackie and adenovirus receptor (Cxadr or CAR) was also 
observed. Increased expression of mesenchymal proteins like N-cadherin (cdh2), Vimentin was 
observed in addition to increased stress fibre formation as detected by phalloidin stain. There 
was increased nuclear expression of EMT transcription factors Snail1, Smad4, and Twist. 
Reduced incorporation of EdU (5-ethynyl-2′-deoxyuridine) and Ki67 intensity confirmed the 
cell cycle arrested, non-proliferative state of NMuMG cells after EMT induction. NMuMG 
cells after 48h of TGFβ treatment showed increased rRNA synthesis assayed by 5-
Fluorouridine (FUrd) incorporation. FUrd is incorporated into the nascent RNA. This increased 
rRNA synthesis was decoupled from proliferation and was accompanied by a modest reduction 
in global protein synthesis. 
Similar pattern of increased rRNA synthesis decoupled from proliferation was observed in 
Py2T mammary cell line. This cell line is obtained from the MMTV-PyMT mouse and 
undergoes EMT upon 48h TGFβ treatment. Increased rRNA synthesis was also observed in  
MCF7 human breast cancer cell line that undergoes EMT after 48h under hypoxic conditions, 
confirming that the observed rRNA synthesis is not unique to the TGFβ stimuli nor cell type 
specific. The increased synthesis of rRNA during EMT was confirmed in vivo in delaminating 
neural crest cells of both chick and mouse embryos during development. The embryos pulsed 
with FUrd/EU and EdU/BrdU showed increased rRNA synthesis in the migrating cell 
populations whereas the cells that were proliferating did not overlap with the migrating cells 
as identified with Snail2 and Sox10. These models show that the observed induction in rRNA 
synthesis during EMT is conserved across species and various EMT-inducing stimuli and 
during development. 
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Increased ribosome biogenesis is observed during EMT and occurs during cell cycle 
arrest 
We further confrimed increased rDNA transcription as measured by 45S pre-rRNA transcript 
after 48h of TGFβ treatment by qRT-PCR. Induced expression of processed rRNA transcripts 
(34S, 28S,18S, and 5.8S) were also observed. Pol I complex proteins including Pol I itself, 
UBF, RRN3 and rRNA processing proteins like, Nucleolin, Fibrillarin, Sirt7 and B23 were also 
upregulated after 48h of TGFβ treatment to accommodate the increased ribosome biogenesis 
program during EMT. To confirm the cell cycle stage accompanying this increased ribosome 
biogenesis, we employed the FUCCI technology. We observed cell cylce arrest and 
synchronization of cells at G1/S after 48h of TGFβ treatment which was accompanied by a 
decrease in cyclin D1 levels and increase in cyclin E levels. These observations show that there 
increased ribosome biogenesis can be detected during G1/S phase in EMT when the cells are 
cell cycle arrested. 
Activation of rDNA Operons observed during EMT 
We performed Chromatin immunoprecipitation assay (ChIP) analysis to study the changes in 
rDNA heterochromatin during the increased ribosome biogenesis that accompanies EMT. 
TIP5, a major component of the nucleolar remodeling complex (NoRC) repressive complex 
showed reduced association to the rDNA promoter and Snail1 promoter after EMT whereas an 
increased association was observed at the E-cadherin promoter. Increased recruiment of the Pol 
I complex components Pol I, UBF and Sirt7 to rDNA casette after EMT were also observed 
consistent with the observation of increased rRNA synthesis. These observations show an 
activation of rDNA operons taking place during EMT, that are otherwise silenced in the 
epithelial cells. 
Regulation of rRNA synthesis during EMT by Snail1 
Chip analysis revealed the recruitment of Snail1 to rDNA promoter, 18S and 28S regions post-
EMT. To further confirm the role of Snail1 in regulation of rRNA synthesis during EMT we 
employed NMUMG-Snail1-ERT2 cells that undergo Snail1 driven EMT upon addition of 4-
hydroxytamoxifen. We observed increased rRNA synthesis pulsing cells with EU (5-Ethnyl 
uridine) which similairly to FUrd gets incorporated into nascent rRNA trancripts, increased 
nucleolar UBF and Fibrillarin in this Snail1 driven EMT model. This finding shows that Snail1 
directly regulates rRNA synthesis during EMT. 
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EMT is hampered by inhibition of ribosome biogenesis  
To determine a potential driving role for de novo ribosome biogenesis in EMT, we inhibited 
ribosome biogenesis by disrupting Pol I complex assembly at rDNA promoters using a small 
molecule inhibitor of CX-5461, at a time point where the EMT process had been initiatied, i.e. 
27h post TGFb treatment. CX-5461 treatment reduced FUrd incorporation and 45S transcript 
levels concomitantly with a reduction in the association of UBF and Snail1 to the rDNA 
promoter. The invasive capacity of the TGFβ treated cells were significantly reduced upon 
treatment with CX-5461. We also observed a reduction in the mesenchymal marker Vimentin 
and stress fibre formation and Snail1 upon CX-5461 treatment. In addition to pharmacological 
inhibition, genetic silencing of the largest subunit of Pol I (Pol1ra) also lead to decreased 
invasiveness and reduced expressed of mesenchymal marker vimentin. These results indicate 
that de novo rRNA synthesis is essential to execute EMT. 
Ribosome biogenesis during EMT is associated with mTORC2 signaling 
mTORC2 is a key driver of EMT and its activation has been linked to its association with the 
mature ribosome. Rictor, a major component of the mTORC2 complex was found to be 
localized to nucleolus and expression was increased upon TGFβ induced EMT. RNase 
treatment resulted in the loss of nucleolar localization of Rictor in the cell, suggesting its 
association with RNA. CX-5461 treament reduced the expression of Rictor consistent with 
reduced mTORC2 signaling and diminished EMT program while mRNA levels of Rictor 
remained unchanged indicating that the response to CX-5461 is post-transcriptional.  
Induced expression levels of Pol I and Rictor in vivo during tumor progression 
We employed MMTV-PyMT mouse model to study the importance of rRNA synthesis during 
tumor progression. The MMTV-PyMT model mimics human breast luminal tumor 
development starting with hyperplasia and progresses through adenoma to early and late 
carcinoma. This mouse models starts to develop tumors at 6 weeks, shows evidence of micro-
metastasis in the lungs at 8 weeks and progresses to carcinoma at 12 weeks. The 12-week 
tumors show increased expression of Pol I as shown by immunofluorescence, especially at the 
invasive front. Ki67 levels reduced as the tumor progressed suggesting that the observed 
increase in rRNA synthesis during tumor progression were coinciding with the non-
proliferative cell population. Increased levels of Rictor were observed during tumor 
progression by IHC. Pol I and Ki67 staining detected in the primary tumor and lung metastases 
of the E0771 mouse model, that is a basal-medullary adenocarcinoma model, followed the 
same pattern. 
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Inhibition of ribosome biogenesis results in differentiation of primary tumors and 
reduces metastasis  
To confirm the contribution of rRNA synthesis in cancer progression and metastasis, we treated 
the MMTV-PyMT mice with two doses of CX-5461 (50mg/kg and 87mg/kg). Both doses of 
CX-5461 reduced the primary tumor volume and significantly reduced metastasis. Histological 
evaluation of the CX-5461 treated tumors showed significant changes in the morphology where 
the tumor appeared to be regressed and differentiated. This differentiation was confirmed by 
increased expression of CK8/18 and nuclear ERa expression by IHC. The expression of 
Snail1/2 was also reduced in the tumors after CX-5461 treatment. These results show that 
treatment with CX-5461 halts the de novo rRNA synthesis program and therby reducing the 
cell’s metastasizing capacity and as well as differentiating the tumors into a beningn phenotype.  
Clinical relevance of the findings were verified in human normal breast and breast cancer 
tisuues. Pol I expression was induced in the tumor tissues as compared to the normal tissue. 
The expression of Pol I was especially high in the triple negative breast cancer compared to the 
ERa+ tumors. Though further studies are required, relevance of Pol I expression in human 
tumors suggests that Pol I can be a possible therapeutic target to inhibit the EMT associated 
ribosome biogenesis. 
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3.2 PAPER II 
Ribosome biogenesis during the Epithelial-to-Mesenchymal Transition mediates a 
unique translation program 
Jake E. Batchelder, Varsha Prakash, Brittany Carson, Randall A. Dass, Matthew M. Parks, Chad M. 
Kurylo, Jennifer M. Feenstra, Johan Hartman, Jonas Bergh, C. Theresa Vincent and Scott C. Blanchard 
EMT is accompanied by extensive changes in transcription and translation 
To determine the translational control of EMT program we performed ribosome profiling on 
NMuMG post 48h of TGFβ treatment. Poly-A-selected mRNA sequencing was performed and 
combined with the ribosomal profiling data to elucidate the transcriptional and translational 
control of EMT. Sets of genes were discovered to be changed at the mRNA level but not at the 
level of ribosome protected fragments (RPF) is defined as ‘translationally’ controlled. 
Ribosome profiling demonstrated that 1336 genes (about 40%) of the 3,143 differentially 
expressed genes were found to be translationally controlled. These results show the existence 
of pervasive translational control during EMT which would have been missed by conventional 
mRNA sequencing studies. New genes identified by these profiling efforts were verified in 
dinstinct EMT models and in patient tissues. 
Translational control of EMT is affected by ribosome biogenesis inhibition 
To determine the relationship between active ribosome biogenesis and translational control of 
EMT, we treated the NMuMG cells with Pol I assembly inhibitor CX-5461 27h after TGFβ 
treatment. Ribosome profiling showed 1478 genes to be differentially expressed between TGFβ 
and TGFβ with CX-5461 while no changes were detectected at the level of mRNA. Ribosome 
concentration was found to be unchanged as revealed by polysome profiles. Out of the 3048 
genes, 824 genes that were differentially expressed after TGFβ treatment were significantly 
changed after inhibition of ribosome biogenesis. About 712 genes out of 824 (85%) showed 
reverted profile matching to those of untreated cells suggesting that around 24% (712/3048) of 
the gene expression changes accompanying the EMT program is driven by active ribosome 
biogenesis. 50% (364/712) of this gene set was found to be translationally controlled and CX-
5461 blocked the upregulation and downregulation of 185 and 179 translationally controlled 
genes respectively. These experiments highlight the existence of an EMT associated ribosome 
biogenesis program contributing to translational control during the EMT program.  
mTORC1 signaling cascade is changed during ribosome biogenesis 
Our profiling studies revealed that post TGFβ treatment mRNA transcripts encompassing short 
and less structured UTRs were reduced which have previously been suggested to be features 
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of mRNA transcripts that are regulated by mTOR signaling. Accordingly, this is suggesting 
that a downregulation of pro-proliferative mTORC1 signaling program occurs during EMT. 
Consistent with this, phosphorylation at serine 2448 of mTOR (p-mTOR 2448) and 
phosphosphorylation of elongation factor eEF2 was observed to be downregulated post EMT. 
Interestingly, these mTORC1 marks were found to be upregulated by CX-5461 treatment. 
These findings reveal that the reduction in rDNA transcription mediated by CX-5461 treatment 
specifically impacts the translational control of gene expression which is intimately linked to 
the pro-proliferative mTORC1 program. 
Elongation Factors are altered during EMT 
We further investigated the other elongation factors contained within the heavy complex given 
that eEF2 phosphorylation is a downstream target of mTORC1 complex. We observed changes 
in expression and localization of the other elongation factors and this correlated with that cells 
post TGFβ treatment were more sensitive when treated with the translation elongation inhibitor 
Didemin B. These data support the notion that there might be changes in the physical translation 
elongation machinery during the EMT program. Collectively, our results demonstrate that 
EMT is accompanied by pervasive translation control and identifies the translation machinery 
and ribosome biogenesis as critical features of EMT that can be selectively targeted for 
therapeutic intervention. 
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3.3 PAPER III 
Wnt5a Signals through DVL1 to Repress Ribosomal DNA Transcription by RNA 
Polymerase I 
Randall A. Dass, Aishe A. Sarshad, Brittany B. Carson, Jennifer M. Feenstra, Amanpreet Kaur, Ales 
Obrdlik, Matthew M. Parks, Varsha Prakash, Damon K. Love, Kristian Pietras, Rosa Serra, Scott C. 
Blanchard, Piergiorgio Percipalle, Anthony M. C. Brown, C. Theresa Vincent 
rDNA transcription is repressed by Wnt5a signaling and is mediated through DVL1 
Non-canonical, Wnt5a has been shown to acts as tumor suppressor in breast cancer. rDNA 
transcription has been implicated in cellular proliferation and is known to be induced by 
oncogenic signals. To determine whether a soluble factor such as Wnt5a could exert its tumor 
suppressive effect through regulation of rRNA biogenesis we determined the 47S pre-rRNA 
transcript in MCF7 cells after treatment with Wnt5a and found that the 47S pre-rRNA transcript 
to be reduced by more than 50%. This reduction was abrogated by a Wnt5a antagonist. Pre-
nascent rRNA synthesis as denoted by FUrd incorporation was also reduced by 60%. This 
repression of rDNA was found to be mediated by gain of DVL1 and a loss of SIRT7 as revealed 
by the ChIP assay to the rDNA promoter, 18S and 28S regions in Wnt5a-expressing MCF7 
cells. DVL1 was expressed in the nuclear and sub-nuclear regions co-localizing with 
Fibrillarin, whereas DVL2 and DVL3 were distributed in the cytoplasmic region, as detected 
by immunofluorescence. Stable transfection of MCF7 and BT549 cell lines with shRNAs 
targeting DVL1 resulted in increased 47S pre-rRNA transcripts accompanied by enlarged 
nucleoli as visualized by AgNOR. Treatment of the shRNA control cells with Wnt5a reduced 
47S transcripts whereas the cells with DVL1 shRNA did not show any significant decrease in 
rDNA transcription. The results observed shows that Wnt5a signaling acts as a tumor 
suppressor by repressing rDNA and this suppression is mediated by gain of DVL1 and a loss 
of SIRT7, suggesting a role of DVL1 as a repressor of Pol I mediated rDNA transcription. 
rDNA is regulated in vivo by Wnt5a signaling 
To determine the effect of Wnt5a signaling on rRNA biogenesis in vivo, we employed MMTV-
PyMT/Wnt5a++ mice. The Wnt5a null mice showed increased expression of Ki67, Sirt7 and 
enlarged nucleolar regions in their tumors when compared to the Wnt5a++ mice supporting a 
tumor suppressive role of Wnt5s by decreasing rDNA transcription resulting in halted tumor 
growth. Survival curves from the Cancer Genome Atlas (TCGA) showed poor prognosis to be 
associated with low expression of Wnt5a, SIRT7 and DVL1. These data support the role of 
Wnt5a signaling to suppress tumor development in vivo by regulating rDNA transcription. 
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4 DISCUSSION AND CONCLUSION 
Our studies have revealed that the EMT program is accompanied by an induction of rRNA 
synthesis that occurs in the absence of cellular proliferation which is independent of stimuli or 
species. We have also shown that blocking de novo rRNA synthesis using Pol I assembly 
inhibitors hampers EMT and subsequent metastasis. These findings challenge the previous 
dogma, that ribosome biogenesis is only necessary for dividing cells and that it occurs without 
phenotypic specificity.  
Interestingly, the EMT cell fate switch driven by de novo ribosome biogenesis occurs at G1/S 
phase of the cell cycle where they are in a cell cycle arrested state. These results also suggest 
that rRNA biogenesis regulation during cell cycle may be distinct in proliferative cells 
compared to cells undergoing EMT. Correspondingly, our investigations suggest that Pol I 
activities much like has been observed for Pol II are also regulated during the cell cycle, and 
in particular during cell cycle arrest at the G1/S transition211. 
The observed de novo ribosome biogenesis was due to the transcriptional activation of the 
rDNA genes that are otherwise silenced by TIP5, a component of the NORC repressive 
complex which dissociates from rDNA genes during EMT. That silenced rDNA genes are 
activated during EMT is in line with that EMT is a developmental program which is reactivated 
in cancer. This suggest the possibility of formation and activation of specific transcriptional 
complexes that interact with Pol I which may be necessary to transcribe a specific set of EMT 
associated rRNAs genes that will ultimately make up the mature ribosome. Animal cells 
contain approximately 300 copies of the mammalian rDNA genes as highly homologous and 
repetitive rDNA repeats located at chromosome 13, 14, 15, 21, and 22212,213; in mice, and in 
humans 12, 15, 16, 18 and 19214–216.  Remarkably, only one precise rDNA sequence of the 
hundreds found in the mammalian genome are currently known. It therefore possible that 
different transcriptional complexes with factors such as Snail are activating unique rDNA 
sequences at distinct chromosomes resulting in the expression of distinct ribosomes. Recent 
studies supports this notion as it has been shown that in bacteria nutrient limitation-induced 
stress changes the expression of encoded rDNA genes which alter the rRNA composition 
within the assembled ribosome217. The expression of these conserved rRNA sequence 
variations within the assembled ribosome resulted in gene expression changes which results in 
changes in cell physiology217. Future studies are now needed to test if these encoded rRNA 
variants in a similar manner play a regulatory role in mammalian cells and specifically during 
EMT. 
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Our observation of the recruitment of Snail1 to rDNA promoter during EMT led to our 
discovery of Snail1 driving rRNA synthesis, which further suggests that Snail1 might directly 
or indirectly associated with the Pol I complex regulating ‘EMT associated’ rDNA 
transcription. Our findings extend Snail’s previous extensive role in Pol II regulation during 
EMT to the Pol I machinery potentially functioning as a pan-RNA polymerase regulator much 
like the oncogene Myc. It also supports a role for Snail not only as a transcriptional repressor 
but transcriptional activator. Further studies will be needed to determine whether Snail also 
regulates Pol III transcription. Moreover, it will be interesting to determine which other 
components in addition to Snail1 that is driving the EMT- associated biogenesis program. 
While the localization of Rictor, the defining component of the mTORC2 complex, in 
proliferating cells was primarily cytoplasmic, we observed increased nucleolar signal of Rictor 
during EMT. This rRNA dependent nucleolar localization of Rictor suggests a novel role of 
newly synthesized rRNA in modulating the mTORC2 kinase activity. This opens up the 
possibility of that newly synthesized rRNAs display a preference for specific associated factors, 
including Rictor, that can bind to the ribosomes and modulate the signaling cascade leading to 
the cell identity switch. There could also be other proteins interacting with these newly 
synthesized rRNAs contributing to a ‘ribo-interactome’ that modulates specialized translation 
based on cues from the interactome profile. Further experiments are required to study this 
potential regulatory axis, for example by further defining the interactome of ribosomes in 
proliferating and EMT cells. The association of Rictor to the newly synthesized rRNAs 
therefore supports a dual role of ribosomes: that they function as both regulators of translation 
and “signaling centers” that execute specialized cellular signaling cascades and functions. This 
preference for associated proteins may stem either from the encoded cues of the transcription 
complex or the sequence variation of rRNAs that are specified to carry out distinct cellular 
programs as mentioned above. Given that this model is correct, it is not absolute number of 
ribosomes being generated during EMT rather which ribosomes that are generated given that 
the number of ribosomes in a cell far exceeds the amount of Rictor molecules.  
The observed induction in rRNA synthesis during EMT was not linked to an increase in global 
protein synthesis, despite the increase in mesenchymal proteins including Snail, Vimentin and 
N-cadherin. Together, these data could potentially suggest a role of the newly synthesized 
rRNA in forming ribosomes that translate mRNAs associated with the mesenchymal 
phenotype. Another interpretation is that the newly synthesized rRNA transcripts might act by 
sequestering factors responsible for pro-proliferative translation, thereby favoring translation 
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of mesenchymal proteins. All these findings suggest a plethora of other ways by which these 
newly synthesized rRNAs could be functioning to drive EMT in cancer progression.  
In line with our in vitro findings, increased Pol I expression was observed during cancer 
progression in a metastatic mouse model and in human triple negative breast tumor samples. 
These expression data support the clinical relevance of our findings and the importance of 
targeting ribosome biogenesis. Mice treated with CX-5461 exhibited significantly reduced 
primary and secondary tumors. Importantly, the primary mouse tumors were differentiated into 
ERa positive phenotype with a more benign morphology after inhibition of ribosome 
biogenesis. This opens up a new therapeutic possibility of targeting aggressive TNBC and 
potentially render these tumors responsive to hormonal therapy. Another possibility to explain 
our findings could be that the Pol I inhibitor might specifically targeting the mesenchymal 
invasive cell population with the induced de novo ribosome biogenesis program resulting in a 
smaller epithelial tumor that is benign and with more proliferative properties which potentially 
can be targeted with conventional anti-proliferative therapies. 
To gain mechanistic insights into the role of ribosome biogenesis during EMT a modified 
ribosomal profiling method combined with RNA sequencing efforts revealed that there were 
pervasive changes both at transcriptional and translation level during EMT. A significant 
percentage of the translationally controlled genes changed when ribosome biogenesis initiation 
was inhibited whereas there were no significant changes in the transcriptionally controlled 
genes. These data suggest that the newly synthesized rRNA driving the EMT program might 
have a regulatory role in controlling the translation of specific transcripts that are responsible 
for the loss of an epithelial cell phenotype and for the acquisition of mesenchymal phenotype. 
These studies also support the notion that the newly generated ribosomes during EMT may be 
distinct in their composition and participating in cellular signaling due to their interactome. 
Future studies will be necessary to determine how such ribosomes are assembled, what specific 
factors these ribosomes are binding, the stability of such ribosomes, how these ribosomes are 
capable of activating signaling cascades and how these ribosomes ultimately are linked to cell 
identity and metastasis. Such studies may reveal important insights into novel means of 
therapeutically targeting metastatic disease by identifying physical distinctions in the 
translation machinery and the unique features associated with the EMT-specific gene 
expression program. 
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